TY - JOUR
T1 - Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases
AU - Gendelman, Howard E.
AU - Anantharam, Vellareddy
AU - Bronich, Tatiana
AU - Ghaisas, Shivani
AU - Jin, Huajun
AU - Kanthasamy, Anumantha G.
AU - Liu, Xinming
AU - McMillan, Jo Ellyn
AU - Mosley, R. Lee
AU - Narasimhan, Balaji
AU - Mallapragada, Surya K.
N1 - Publisher Copyright:
© 2015 The Authors.
PY - 2015
Y1 - 2015
N2 - Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes.
AB - Interest in nanoneuromedicine has grown rapidly due to the immediate need for improved biomarkers and therapies for psychiatric, developmental, traumatic, inflammatory, infectious and degenerative nervous system disorders. These, in whole or in part, are a significant societal burden due to growth in numbers of affected people and in disease severity. Lost productivity of the patient and his or her caregiver, and the emotional and financial burden cannot be overstated. The need for improved health care, treatment and diagnostics is immediate. A means to such an end is nanotechnology. Indeed, recent developments of health-care enabling nanotechnologies and nanomedicines range from biomarker discovery including neuroimaging to therapeutic applications for degenerative, inflammatory and infectious disorders of the nervous system. This review focuses on the current and future potential of the field to positively affect clinical outcomes.
KW - Diagnostics
KW - Drug development
KW - Nanoneuromedicine
KW - Nanotechnology
KW - Neurodegenerative disorders
UR - http://www.scopus.com/inward/record.url?scp=84933497981&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933497981&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2014.12.014
DO - 10.1016/j.nano.2014.12.014
M3 - Review article
C2 - 25645958
AN - SCOPUS:84933497981
SN - 1549-9634
VL - 11
SP - 751
EP - 767
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 3
ER -